

Patients (child or adult) living in the North of England with health (physical or neurodevelopmental) concerns and who were exposed in utero to specific antiseizure medicines. This will include:

- Patients not diagnosed with a Fetal Valproate Spectrum Disorder (FVSD) or another Fetal Anticonvulsant Syndrome (FACS) but with a concern about one or more aspects of physical health and development or neurodevelopment in relation to the in-utero exposure.
- Patients with an FVSD diagnosis or FACS diagnosis who require an updated clinical management plan.

The exposure eligibility is not limited to an indication for maternal epilepsy or seizures.

As this is a pilot service, there are limitations to the scope of the service.